Corient Private Wealth
TGTX icon

Corient Private Wealth’s TG Therapeutics TGTX Stock Holding History

Corient Private Wealth’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.22M Sell
40,393
-1,014
-2% -$41.5K ﹤0.01% 1338
2026
Q1 		$1.38M Sell
41,407
-357
-0.9% -$10.6K ﹤0.01% 1465
2025
Q4 		$1.24M Buy
41,764
+1,469
+4% +$48K ﹤0.01% 1392
2025
Q3 		$1.46M Sell
40,295
-57
-0.1% -$1.88K ﹤0.01% 1235
2025
Q2 		$1.45M Sell
40,352
-365
-0.9% -$13.6K ﹤0.01% 1186
2025
Q1 		$1.61M Sell
40,717
-6,661
-14% -$224K ﹤0.01% 1066
2024
Q4 		$1.43M Sell
47,378
-35,309
-43% -$1.01M ﹤0.01% 1143
2024
Q3 		$1.93M Sell
82,687
-15,669
-16% -$342K ﹤0.01% 1113
2024
Q2 		$1.75M Buy
98,356
+25,975
+36% +$414K ﹤0.01% 1083
2024
Q1 		$1.1M Sell
72,381
-21,000
-22% -$335K ﹤0.01% 1285
2023
Q4 		$1.59M Buy
93,381
+65,220
+232% +$758K ﹤0.01% 1106
2023
Q3 		$235K Buy
28,161
+10,400
+59% +$145K ﹤0.01% 1846
2023
Q2 		$441K Buy
+17,761
New +$459K ﹤0.01% 1512

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Corient Private Wealth's TGTX Position: Q2 2026 in Review

Corient Private Wealth reduced its TG Therapeutics (TGTX) stake by 2.4% in Q2 2026, selling an estimated $41.5K and leaving 40,393 shares worth $2.22M. The position accounts for ﹤0.01% of the portfolio, ranked #1338.

Corient Private Wealth first reported a position in TGTX in Q2 2023 and has held it in 13 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Corient Private Wealth held 40,393 shares of TG Therapeutics worth $2.22M as of Q2 2026.
  • Corient Private Wealth sold 1,014 TG Therapeutics shares in Q2 2026, an estimated $41.5K.
  • TG Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1338 holding.
  • Corient Private Wealth first reported a position in TG Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.